Clascoterone is a topical anti-androgen that blocks androgen receptors directly at the follicle without entering systemic circulation in meaningful amounts. It is already FDA-approved for acne under the brand name Winlevi, and its investigational formulation for androgenetic alopecia (AGA), known as Breezula, has generated Phase II data that caught the attention of dermatologists looking for alternatives to finasteride. The appeal is straightforward: local androgen blockade without the sexual side effects that keep many men from starting treatment. BaldingAI lets you capture baseline density scans before trialing any new treatment, so you have objective data to compare against rather than relying on mirror impressions weeks later.
TL;DR
- Clascoterone is a competitive androgen receptor antagonist that works locally in skin tissue, unlike finasteride which inhibits 5-alpha reductase systemically.
- Phase II trial data (Cassiopea, 2023) showed statistically significant improvements in target area hair count versus vehicle over 12 months.
- Systemic absorption is minimal. Cortexolone, its primary metabolite, does not suppress serum DHT or testosterone levels at clinically relevant doses.
- Clascoterone is FDA-approved for acne (Winlevi, 1% cream) but not yet approved for hair loss. The AGA formulation (Breezula, 7.5% solution) is still in clinical development.
- If and when it becomes available, tracking density changes over 6 to 12 months will be essential for evaluating personal response.
Important
This article is educational and not medical advice. If you are worried about sudden shedding, scalp symptoms, or side effects, talk to a licensed clinician.
What is clascoterone and how does it work?
Clascoterone (cortexolone 17-alpha-propionate) is a steroidal anti-androgen designed for topical application. Its mechanism is competitive antagonism at the androgen receptor (AR). In practical terms, clascoterone binds to the same receptor that dihydrotestosterone (DHT) uses to trigger follicular miniaturization, but it does not activate the receptor. It occupies the binding site and prevents DHT from docking, which interrupts the downstream signaling cascade that shortens anagen and shrinks the follicle.
This is a fundamentally different approach from finasteride and dutasteride. Those drugs are 5-alpha reductase inhibitors: they reduce the conversion of testosterone to DHT throughout the body, lowering serum DHT levels by roughly 70% (finasteride) or 90% (dutasteride). Clascoterone does not touch DHT production at all. It lets your body produce normal amounts of DHT but blocks that DHT from activating receptors in the scalp. The distinction matters because the systemic effects of DHT suppression are what produce the side-effect profile that concerns many patients.
Once applied to the scalp, clascoterone is rapidly metabolized into cortexolone, a compound with minimal androgenic or anti-androgenic activity. This rapid local metabolism is what limits systemic exposure. Pharmacokinetic studies have shown that even at the higher concentrations used for AGA (7.5%), plasma levels of clascoterone remain well below thresholds associated with systemic anti-androgenic effects.
How it differs from topical finasteride
Topical finasteride has gained traction as a way to reduce scalp DHT while minimizing systemic absorption compared to oral finasteride. But topical finasteride still inhibits 5-alpha reductase, and studies show it does reduce serum DHT to some degree, typically by 25 to 35% depending on formulation and dose (Piraccini et al., 2022). The reduction is smaller than the oral form, but it is not zero.
Clascoterone operates through a completely separate pathway. Because it is a receptor blocker rather than an enzyme inhibitor, it does not reduce circulating DHT at all. A 2020 pharmacokinetic analysis published in the Journal of Drugs in Dermatology confirmed that clascoterone 1% cream (the acne formulation) did not produce statistically significant changes in serum testosterone, DHT, or cortisol levels versus placebo. The AGA formulation uses a higher concentration (7.5%), but the rapid local metabolism to cortexolone still limits systemic activity.
For men who experienced sexual side effects on finasteride or who are unwilling to risk them, this pharmacological profile is what makes clascoterone compelling. It is not simply another topical version of the same drug class. It is a different mechanism entirely.
Phase II trial results for androgenetic alopecia
Cassiopea S.p.A., the Italian pharmaceutical company developing clascoterone, released Phase II results for Breezula (clascoterone 7.5% solution) in male AGA. The trial was a randomized, double-blind, vehicle-controlled study that enrolled men with Norwood-Hamilton grades III to V androgenetic alopecia. Participants applied the solution to the scalp twice daily for 12 months.
Results presented at the 2023 American Academy of Dermatology (AAD) annual meeting showed that clascoterone 7.5% produced statistically significant increases in target area hair count (TAHC) compared to vehicle at both 6 and 12 months. The improvements were described as clinically meaningful, with hair count increases in the range that dermatologists consider relevant for patient-perceptible change. Exact figures from the abstract indicated a mean change from baseline of approximately +10 to +12 hairs per cm2 in the treatment group versus roughly -1 to +2 in the vehicle group at 12 months.
Safety data from the same trial were reassuring. No treatment-related sexual adverse events were reported. The most common side effects were mild application site reactions (erythema, pruritus) that resolved without intervention. Hormonal panels drawn throughout the study showed no significant differences between clascoterone and vehicle groups in serum testosterone, DHT, LH, or FSH levels.
It is important to contextualize these numbers. The Phase II trial was relatively small compared to the pivotal trials that led to finasteride approval (which enrolled over 1,500 men). Cassiopea has stated that Phase III trials for the AGA indication are planned, but as of early 2026, those trials have not yet reported results. The efficacy signal is promising, but the dataset is not yet at the level of evidence that finasteride or minoxidil have accumulated over decades.
Current FDA and regulatory status
Clascoterone 1% cream (Winlevi) received FDA approval in August 2020 for the treatment of acne vulgaris in patients 12 years and older. It was the first new acne drug mechanism approved in roughly 40 years. The approval was based on two Phase III trials (CB-03-01/25 and CB-03-01/26) that demonstrated superiority over vehicle in reducing inflammatory and non-inflammatory acne lesions.
The AGA formulation (Breezula, clascoterone 7.5% solution) does not have FDA approval. It is an investigational product. Some dermatologists have explored off-label use of Winlevi (the 1% acne cream) on the scalp, but the lower concentration and cream vehicle were not designed for scalp application. The AGA-specific formulation uses a solution vehicle at a 7.5-fold higher concentration, and the efficacy data from Phase II is specific to that formulation.
If you are considering clascoterone for hair loss, it is worth having a direct conversation with a dermatologist about the current status. Using an acne cream off-label on the scalp is not the same as using the purpose-built AGA formulation, and you should not assume the same results.
Who might benefit most from clascoterone?
The patient profile most likely to benefit from clascoterone for AGA, if and when it reaches market, falls into a few categories. First: men who have discontinued finasteride due to side effects or who are unwilling to start it. For this group, clascoterone would represent the first topical anti-androgen with a plausible side-effect advantage. Second: men who are already on minoxidil and want to add an anti-androgen component without the systemic DHT suppression of finasteride. Third: women with androgenetic alopecia, for whom systemic anti-androgens like spironolactone carry their own side-effect considerations and for whom finasteride is not FDA-approved.
It is less likely to replace finasteride for men who tolerate it well, because finasteride has a far deeper evidence base and a known efficacy ceiling. The role of clascoterone, at least initially, is more likely as an alternative for the finasteride-intolerant or finasteride-averse population.
How to track response if you trial clascoterone
Any new treatment for androgenetic alopecia requires a structured tracking protocol to determine whether it is working. This is especially true for a novel agent like clascoterone, where personal response data is valuable because the published dataset is still small.
Before your first application, take a full set of baseline scans covering your hairline, temples, crown, and part line. Use consistent lighting, angle, and hair state. BaldingAI standardizes these variables across scans so that changes in density scores reflect actual follicular changes rather than photographic noise. Scan every one to two weeks and log the date you started treatment, application frequency, and any co-treatments you are using.
Based on the Phase II timeline, plan to evaluate at 6 months minimum. Follicular miniaturization reversal is a slow biological process. Early responders may see density shifts at 3 to 4 months, but drawing conclusions before 6 months risks false negatives. If your density trend is flat or declining at 12 months, that is a clear signal to reassess with your dermatologist.
The bottom line
Clascoterone represents a genuinely new mechanism for treating androgenetic alopecia: local androgen receptor blockade without systemic DHT suppression. The Phase II data is encouraging, the safety profile is clean, and the pharmacological rationale is sound. But it is not yet approved for hair loss, the evidence base is thin compared to established treatments, and the AGA-specific formulation is not commercially available.
If clascoterone eventually clears Phase III and reaches the market, it will likely fill an important gap for patients who cannot or will not tolerate finasteride. Until then, the responsible approach is to stay informed, discuss it with a board-certified dermatologist, and track whatever treatment you do use with enough rigor to know whether it is actually working.
Track density changes when trialing new treatments
BaldingAI gives you objective density scores so you can measure whether a new treatment is working over 6 to 12 months of consistent tracking.
Your scans stay private. Delete or export anytime.
Sources: Hebert et al. 2020, Journal of Drugs in Dermatology, Piraccini et al. 2022, Dermatologic Therapy, Cassiopea S.p.A. Phase II data presentations, AAD 2023.
